207 related articles for article (PubMed ID: 24056254)
1. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
2. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.
Jiang Y; Bernard D; Yu Y; Xie Y; Zhang T; Li Y; Burnett JP; Fu X; Wang S; Sun D
J Biol Chem; 2010 Jul; 285(27):21023-36. PubMed ID: 20413594
[TBL] [Abstract][Full Text] [Related]
3. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
[TBL] [Abstract][Full Text] [Related]
4. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
6. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
[TBL] [Abstract][Full Text] [Related]
7. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
Zhang Q; Wu X; Zhou J; Zhang L; Xu X; Zhang L; You Q; Wang L
Eur J Med Chem; 2021 Jan; 210():112959. PubMed ID: 33109397
[TBL] [Abstract][Full Text] [Related]
9. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.
Hallett ST; Pastok MW; Morgan RML; Wittner A; Blundell KLIM; Felletar I; Wedge SR; Prodromou C; Noble MEM; Pearl LH; Endicott JA
Cell Rep; 2017 Oct; 21(5):1386-1398. PubMed ID: 29091774
[TBL] [Abstract][Full Text] [Related]
10. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
Jiang F; Wang HJ; Bao QC; Wang L; Jin YH; Zhang Q; Jiang D; You QD; Xu XL
Bioorg Med Chem; 2016 Nov; 24(21):5431-5439. PubMed ID: 27647369
[TBL] [Abstract][Full Text] [Related]
11. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
12. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.
Sreeramulu S; Gande SL; Göbel M; Schwalbe H
Angew Chem Int Ed Engl; 2009; 48(32):5853-5. PubMed ID: 19585625
[No Abstract] [Full Text] [Related]
15. Design of Disruptors of the Hsp90-Cdc37 Interface.
D'Annessa I; Hurwitz N; Pirota V; Beretta GL; Tinelli S; Woodford M; Freccero M; Mollapour M; Zaffaroni N; Wolfson H; Colombo G
Molecules; 2020 Jan; 25(2):. PubMed ID: 31952296
[TBL] [Abstract][Full Text] [Related]
16. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
17. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
Zhao M; Ma J; Zhu HY; Zhang XH; Du ZY; Xu YJ; Yu XD
Mol Cancer; 2011 Aug; 10():104. PubMed ID: 21871133
[TBL] [Abstract][Full Text] [Related]
18. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
20. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
